CYTK Stock - Cytokinetics, Incorporated
Unlock GoAI Insights for CYTK
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $18.47M | $7.53M | $94.59M | $70.43M | $55.83M |
| Gross Profit | $-320,934,000 | $-322,593,000 | $-146,225,000 | $-89,510,000 | $-41,123,000 |
| Gross Margin | -1737.2% | -4284.1% | -154.6% | -127.1% | -73.7% |
| Operating Income | $-536,248,000 | $-496,205,000 | $-324,202,000 | $-186,313,000 | $-93,943,000 |
| Net Income | $-589,526,000 | $-526,244,000 | $-388,955,000 | $-215,314,000 | $-127,290,000 |
| Net Margin | -3191.1% | -6988.6% | -411.2% | -305.7% | -228.0% |
| EPS | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 |
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Visit WebsiteEarnings History & Surprises
CYTKEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-1.48 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-1.59 | $-1.54 | +3.1% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-1.34 | $-1.12 | +16.4% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-1.41 | $-1.36 | +3.5% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-1.29 | $-1.26 | +2.3% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-1.27 | $-1.36 | -7.1% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-1.02 | $-1.31 | -28.4% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-1.16 | $-1.33 | -14.7% | ✗ MISS |
Q1 2024 | Feb 27, 2024 | $-1.03 | $-1.38 | -34.0% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.72 | $-1.35 | -87.5% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-1.23 | $-1.34 | -8.9% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-1.24 | $-1.38 | -11.3% | ✗ MISS |
Q1 2023 | Mar 1, 2023 | $-1.22 | $-1.45 | -18.9% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-1.19 | $-1.28 | -7.6% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-1.04 | $-0.23 | +77.9% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $-0.93 | $-1.02 | -9.7% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $-0.89 | $-0.36 | +59.6% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $-0.75 | $-0.95 | -26.7% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.65 | $-0.86 | -32.3% | ✗ MISS |
Latest News
Frequently Asked Questions about CYTK
What is CYTK's current stock price?
What is the analyst price target for CYTK?
What sector is Cytokinetics, Incorporated in?
What is CYTK's market cap?
Does CYTK pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CYTK for comparison